Article Text

Download PDFPDF
Update on dual antiplatelet therapy for percutaneous coronary intervention
  1. Abhiram Prasad,
  2. David R Holmes
  1. The Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
  1. Dr Abhiram Prasad, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; prasad.abhiram{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Platelet activation is central in the vascular response to percutaneous coronary intervention (PCI). In addition, patients with coronary artery disease (CAD), particularly those with an acute coronary syndrome (ACS), have pre-existing platelet hyper-reactivity. Together, these are among the factors that predispose to stent thrombosis (ST). Thus, dual antiplatelet therapy (DAT), which consists of aspirin and a thienopyridine, forms the cornerstone of pharmacotherapy following PCI with the goal of reducing ST, as well as ischaemic events related to the underlying CAD. Adherence to DAT, and the need for a longer duration of treatment, has become even more important for patients receiving drug-eluting stents (DES), as concerns have been raised regarding the increased risk of very late ST (>1 year) with the current generation of stents.1 Table 1 summarises the most recent guidelines on DAT following PCI which have been jointly published by the American College of Cardiology (ACC), American Heart Association (AHA) and Society for Cardiovascular Angiography and Interventions (SCAI).2 3 Despite the routine use of clopidogrel, there is uncertainty about the optimal timing, dose and duration of thienopyridine therapy, and there is a lack of consensus on the management of patients requiring non-cardiac surgery or chronic anticoagulation while being treated with DAT.

View this table:
Table 1 ACC/AHA/SCAI recommendations for the use of antiplatelet agents in patients requiring PCI2 3


Although current practice in many parts of the world is to administer clopidogrel in the catheterisation laboratory at the time of ad hoc PCI, several clinical trials have evaluated the efficacy of pretreatment (table 2).48 Overall, the data suggest a potential benefit of pretreatment with the 300 mg loading dose, though both PCI-CURE and PCI-CLARITY represent analyses in which the decision to perform PCI was made after randomisation to the two loading strategies. It appears that a 300 mg clopidogrel loading dose needs to be administered at least 6 h prior to …

View Full Text


  • Competing interests: None.